These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33392263)

  • 1. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.
    Aigner L; Pietrantonio F; Bessa de Sousa DM; Michael J; Schuster D; Reitsamer HA; Zerbe H; Studnicka M
    Front Mol Biosci; 2020; 7():610132. PubMed ID: 33392263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
    Hoxha M; Rovati GE; Cavanillas AB
    Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asthma pharmacotherapy: an update on leukotriene treatments.
    Trinh HKT; Lee SH; Cao TBT; Park HS
    Expert Rev Respir Med; 2019 Dec; 13(12):1169-1178. PubMed ID: 31544544
    [No Abstract]   [Full Text] [Related]  

  • 5. Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.
    Camera M; Canzano P; Brambilla M; Rovati GE
    Front Pharmacol; 2022; 13():784214. PubMed ID: 35211011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma.
    Volovitz B; Tabachnik E; Nussinovitch M; Shtaif B; Blau H; Gil-Ad I; Weizman A; Varsano I
    J Allergy Clin Immunol; 1999 Dec; 104(6):1162-7. PubMed ID: 10588996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes.
    Funk CD; Ardakani A
    Front Pharmacol; 2020; 11():1214. PubMed ID: 32848802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases.
    Meshram D; Bhardwaj K; Rathod C; Mahady GB; Soni KK
    Recent Pat Inflamm Allergy Drug Discov; 2020; 14(1):15-31. PubMed ID: 32000655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
    Shimbori C; Shiota N; Okunishi H
    Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of leukotriene receptor antagonists (LTRAs) as complementary therapy in asthma.
    Bjermer L; Diamant Z
    Monaldi Arch Chest Dis; 2002 Feb; 57(1):76-83. PubMed ID: 12174707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma.
    Bisgaard H
    Allergy; 2001; 56 Suppl 66():7-11. PubMed ID: 11421935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
    Al-Amran FG; Hadi NR; Hashim AM
    Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model.
    Ujino M; Sugimoto N; Koizumi Y; Ro S; Kojima Y; Asae KH; Yamashita N; Ohta K; Nagase H
    Allergol Int; 2017 Sep; 66S():S21-S26. PubMed ID: 28647381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
    Izumo T; Kondo M; Nagai A
    Life Sci; 2007 Apr; 80(20):1882-6. PubMed ID: 17397875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
    Smith LJ
    Arch Intern Med; 1996 Oct; 156(19):2181-9. PubMed ID: 8885816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication.
    Muraki M; Imbe S; Sato R; Ikeda Y; Yamagata S; Iwanaga T; Tohda Y
    Int Immunopharmacol; 2009 Oct; 9(11):1337-41. PubMed ID: 19706339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
    Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
    Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of leukotrienes in inflammation and leukotriene inhibitors].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
    Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
    Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A leukotriene receptor antagonist modulates iNOS in the lung and in a leukotriene-free cell model.
    Offer S; Shoseyov D; Bibi H; Eliraz A; Madar Z
    Nitric Oxide; 2003 Aug; 9(1):10-7. PubMed ID: 14559427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.